## Glenmark Pharmaceuticals Limited (GLENMARK) Stock Investment Report - December 20, 2024

**1. Company Overview:**

Glenmark Pharmaceuticals Limited (GLENMARK) is a pharmaceutical company listed on the NSE (National Stock Exchange of India) since February 7, 2000.  It operates in the Pharmaceuticals industry and holds a position within the mid-cap segment of the Indian pharmaceutical market.  The company is involved in the research, development, manufacturing, and marketing of a wide range of pharmaceutical products.

**2. Market Data Analysis:**

| Metric                     | Value          | Notes                                                              |
|-----------------------------|-----------------|----------------------------------------------------------------------|
| Current Price               | ₹1,545.00       |                                                                      |
| Percentage Change (PChange) | 0.27%           | Positive change indicating slight upward momentum.                     |
| Pre-Open Activity          | ₹1,530.05       | Opened lower than the previous close, suggesting some initial selling pressure. |
| Week High                    | ₹1,830.95       | Significant high indicating potential for further price appreciation. |
| Week Low                     | ₹771.00         | Significant low indicating considerable volatility.                   |
| VWAP                        | ₹1,546.06       | Close to the current price, suggesting fair valuation.              |
| Sector PE                   | 0               | Data unavailable.                                                    |
| Symbol PE                   | 0               | Data unavailable.                                                    |
| Delivery Percentage         | 50.55%          | Moderate delivery percentage, indicating a mix of long-term and short-term investors. |
| Market Depth                | Low              | Order book data unavailable, but pre-open activity suggests low market depth. |


**3. Financial Performance:**

The following table summarizes Glenmark's financial performance over the past five quarters.  Note that the data provided includes both audited and unaudited figures.  Further analysis would require access to complete audited statements.

| Quarter Ending      | Revenue (₹ in Lakhs) | Expenses (₹ in Lakhs) | Profit After Tax (₹ in Lakhs) | Diluted EPS (₹) |
|----------------------|-----------------------|-----------------------|-----------------------------|-----------------|
| 30-Sep-2024 (U)     | 271917.6              | 192411.7              | 59505.6                     | 21.09            |
| 30-Jun-2024 (U)     | 238518.5              | 176687.1              | 45373.1                     | 16.08            |
| 31-Mar-2024 (A)     | 293449.3              | 178656.1              | 461369.5                    | 163.5           |
| 31-Dec-2023 (U)     | 162391.1              | 167413                | -2040.9                     | -0.72            |
| 30-Sep-2023 (U)     | 227963.3              | 187059.8              | 30235.4                     | 10.72            |

**Key Observations:**  Significant volatility in profitability is observed across quarters.  The March 2024 quarter shows exceptionally high profit, which needs further investigation to determine if this is sustainable or due to exceptional items.  The recent quarters show a mixed trend, with some quarters showing profit and others showing losses.  Key financial ratios (e.g., ROE, ROA, Debt-to-Equity) are unavailable for a comprehensive analysis.

**4. Corporate Actions and Announcements:**

Glenmark has consistently paid dividends over the past several years, with the most recent dividend of ₹2.50 per share having an ex-date of September 13, 2024.  Recent announcements include several press releases and updates regarding acquisitions and analyst meetings.  These announcements suggest ongoing corporate activity and potential for future growth.  However, the specifics of the acquisitions require further investigation.

**5. Shareholding Patterns:**

| Quarter Ending | Promoter & Promoter Group | Public | Shares held by Employee Trusts | Total |
|-----------------|---------------------------|--------|-------------------------------|-------|
| 30-Sep-2023     | 46.65%                     | 53.35% | 0.00%                         | 100.00%|
| 31-Dec-2023     | 46.65%                     | 53.35% | 0.00%                         | 100.00%|
| 31-Mar-2024     | 46.64%                     | 53.36% | 0.00%                         | 100.00%|
| 30-Jun-2024     | 46.65%                     | 53.35% | 0.00%                         | 100.00%|
| 30-Sep-2024     | 46.65%                     | 53.35% | 0.00%                         | 100.00%|

**Key Observations:**  Shareholding patterns remain relatively stable over the past year, with consistent promoter and public holdings.  This suggests a stable ownership structure.

**6. Volatility and Risk Assessment:**

The stock exhibits high volatility, as evidenced by the significant difference between the week's high and low.  The CM Annual Volatility of 36.68% further confirms this.  The risk-reward profile is currently high risk, high reward due to the potential for significant price swings.  A more detailed risk assessment would require analyzing beta and other risk metrics.

**7. Advantages of Buying the Stock:**

* Consistent dividend payouts.
* Ongoing corporate actions suggesting growth potential.
* Relatively stable shareholding pattern.

**8. Disadvantages and Risks:**

* High volatility and significant price swings.
* Inconsistent financial performance across quarters.
* Lack of complete financial data for thorough analysis.
* Dependence on external market factors affecting the pharmaceutical sector.

**9. Investment Horizon Recommendations:**

* **Short-term (less than 3 months): Hold.** The recent price movement is uncertain, and the high volatility makes short-term trading risky.  Waiting for clearer price trends is advisable.

* **Medium-term (3 to 12 months): Hold.**  The medium-term outlook depends on the success of the announced acquisitions and the company's ability to improve its financial consistency.  Further monitoring of financial reports is crucial.

* **Long-term (1 year and beyond): Hold/Consider Buy (with caution).**  Glenmark's consistent dividend payouts and stable shareholding structure are positive long-term indicators. However, the high volatility and inconsistent financial performance warrant caution.  A thorough fundamental analysis, including key financial ratios and industry outlook, is necessary before a strong buy recommendation.


**10. Stock and Analysis Scoring:**

**Stock Score (out of 10): 6.0**

* Financial Health: 5/10 (Inconsistent profitability, needs further investigation)
* Market Performance: 6/10 (Moderate price change, high volatility)
* Volatility and Risk: 4/10 (High volatility, high risk)
* Corporate Actions & Governance: 7/10 (Consistent dividends, active corporate actions)
* Shareholding Patterns: 8/10 (Stable shareholding structure)

**Analysis Score (out of 10): 7.0**

* Completeness and Data Utilization: 7/10 (Some data points missing, but most data used effectively)
* Accuracy and Clarity: 8/10 (Analysis is clear and well-structured)
* Professional Formatting: 9/10 (Report is well-formatted and easy to read)


**11. Professional Recommendation Summary:**

Glenmark Pharmaceuticals presents a mixed investment picture. While the company demonstrates positive aspects like consistent dividend payments and a stable shareholding structure, its high volatility and inconsistent financial performance pose significant risks.  A "Hold" recommendation is given for the short and medium term, pending further clarification on financial performance and the outcome of recent corporate actions.  A cautious "Hold/Consider Buy" is suggested for the long term, contingent upon a more comprehensive fundamental analysis and a positive outlook for the pharmaceutical sector.  Investors should proceed with caution and conduct thorough due diligence before making any investment decisions.
